An observational study in Brain Injury, Acute, sponsored by Boston Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Boston Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 312 studies in Brain Injuries with a site in United States — 57 open to participants now, 69 under way, none of them phase 3. Brain Injuries · United States.
Among the 312 studies in Brain Injuries with a site in United States, this one is the 13th largest by planned enrollment of the 84 observational ones that give a count, is one of 16 that started in 2024, is one of 85 observational ones, reaches primary completion later than 62 of the 68 other live ones, and was the 263rd registered.
947 studies on the registry are indexed under Brain Injuries; 236 are open to participants now.
Browse Brain Injuries studies →57 of the 312 studies in Brain Injuries with a site in United States are open now. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
Bridget LaMonica Ostrem, M.D., Ph.D. · Sites in United States
Ages 3 wk–20 wk
Children's Mercy Hospital Kansas City · Sites in United States
Ages up to 17
Peter C. Gerszten, MD · Sites in United States
Ages 21–75 · Healthy volunteers
Pravat Mandal · Sites in United States
Ages 30–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 153 Brain Injuries studies recruiting now, 76 (50%) set no upper age limit and 55 (36%) stop at 75 or younger; 39 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
312 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 35 · Phase 3 9 · Phase 4 16
First in 1987; this study’s year is marked. 16 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 720 is above the median of 100 across 302 observational studies indexed under Brain Injuries.
Median enrollment 42 across the 223 interventional studies, 85 across the 84 observational. Of the 207 that completed or were terminated, 67 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 312 have an industry lead sponsor. The 10 most frequent:
Boston Medical Center is the lead sponsor of 323 studies on the registry; 33 are open to participants now.
Of its 34 completed or terminated interventional studies of FDA-regulated products, 28 (82%) have results posted.
Boston Medical Center has 1 study filed under Brain Injuries — fewer than ten, so there is no comparison to draw.
19 of the studies in Brain Injuries with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07485361University of California, Los AngelesfNIRS for Disorders of Consciousness | 2026-12 |
| NCT06725108University of ChicagoHemodynamic ABI Monitor | 2026-12-06 |
| NCT05708092Icahn School of Medicine at Mount SinaiNRF for Improved Re-Entry Outcomes for Offenders With Brain Injury (Brain Injury RE) | 2026-12-31 |
| NCT06899971Boston Children's HospitalThe Association Between Tau & GFAP and Postoperative Neurological Impairment in Patients Undergoing Cardiac Surgery | 2026-12-31 |
| NCT06855186Henry M. Jackson Foundation for the Advancement of Military MedicineSymptom-Targeted Approach to Rehabilitation for Concussion (STAR-C) | 2026-12-31 |
Add all 19 to your calendar (.ics) → With an account.
Among the 312 studies in Brain Injuries with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Life-threatening mass effect (LTME) arises when brain swelling displaces or compresses crucial midline structures subsequent to acute brain injuries (ABIs) like traumatic brain injury (TBI), ischemic stroke (IS), and intraparenchymal hemorrhage (IPH), which can manifest rapidly within hours or more gradually over days. Despite advancements in surgical management, significant gaps in understanding persist regarding optimal monitoring and therapeutic approaches. The current standard for identifying LTME involves neurologic decline in conjunction with radiographic evidence or increased intracranial pressure (ICP) indicating space-occupying mass effect. However, in critically ill patients, reliance on subjective physical exam findings, such as decreased arousal, often leads to delayed recognition, occurring only after catastrophic shifts have already occurred.
The goal of this study is to determine the association of non-invasive biomarkers with neurologic deterioration, and to determine whether non-invasive biomarker inclusion improves detection of outcome and decline.
The investigators propose to use various non-invasive methods to monitor ICP as adjuncts in detecting deteriorating mass effect. These methods include quantitative pupillometry, radiographic data, laboratory data, and other bedside diagnostic tests available including electroencephalography (EEG), skull vibrations detected via brain4care device, optic nerve sheath diameter assessment (ONSD), and ultrasound-guided eyeball compression. Some of these methods will be measured *only* for the purposes of the research study (such as skull vibrations via brain4care). Other measurements, such as quantitative pupillometry, will represent additional measurements beyond those already being collected for clinical care. This research study is necessary to understand the association of these non-invasive biomarkers with neurological decline and outcomes while considering potential confounding factors.
Eligible patients will be recruited on admission to the intensive care unit (ICU) at Boston Medica Center followed by the Neurointensive care team.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Sub-exclusion criteria for specific non-invasive measurements include:
Eligible patients will be recruited on admission to the ICU followed by the Neurointensive care team. Demographic, invasive ICP monitoring data, clinical, laboratory, diagnostic, treatment (medical and surgical) and outcome data will be collected. Data will be collected from non-invasive devices using either clinical review from the chart, or if not available and/or used for additional measurements, from the device (smartguard for pupillometry, imaging, EEG data, Brain4care data).
Neurologic Deterioration
Neurologic deterioration will be assessed as a dichotomous variable (yes/no) defined as a negative change in any of the following: level of consciousness, agaze, arm motor function, leg motor function, or language. The participants' medical chart will be reviewed for documentation of persistent change.
Time frame: 5 years
Glasgow Coma Scores
The Glasgow Coma Scale (GCS) is a 15-point scale used to evaluate a person's state of consciousness. A score of 3 is the lowest possible and indicates a deep coma or death, while a score of 15 is the highest and indicates a fully awake person. A lower score generally means a deeper coma.
Time frame: 5 years
Number of participant deaths during hospitalization
This data will be abstracted from medical records..
Time frame: 5 years
Functional outcome at hospital discharge
This will be assessed by Modified Rankin Scale (mRS), a 6 point disability scale with possible scores ranging from 0 to 5, higher scores indicating greater disability and where 0-2 is generally considered a good outcome with individuals assuming complete functional independence. A separate category of 6 is usually added for patients who expire. Data will be abstracted from medical records on review of patient notes and discharge summaries to obtain amRS for each participant.
Time frame: 5 years
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Sep 2030, 72 months after the start.
Of 144 non-industry observational studies under Brain Injuries, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 73. This study's planned 72 months is above that.
Counting every sponsor, half of 149 studies reached it within 31 months; a quarter within 16 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.